jeudi 12 mars 2020

Onco Actu du 12 mars 2020


3.4.1 CHIMIOPRÉVENTION - ASPIRINE



Low-dose aspirin linked to reduced liver cancer risk [Karolinska Institutet]










4.10 DÉP., DIAG. & PRONO. - POUMON



Researchers identify marker that may predict whether lung cancer likely to spread [Tulane University]











4.12 BIOPSIES LIQUIDES



Microbiome-Based Cancer Dx Emerges From Cancer Genome Atlas Reanalysis [Genome Web]











Microbial signatures in the blood could offer new avenue for liquid biopsies to detect cancer [STAT]










AI finds microbial signatures in tumours and blood across cancer types [Nature]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



Half of people in the US would sell their genetic data for $95 [New Scientist]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Systematic Viability Profiling of the Anticancer Potential of Non-Oncology Drugs [ESMO]











Back to the drawing board for triple-negative breast cancer targets, researchers propose new combo approach [EndPoints]











NIH researchers successfully stop blood vessel, tumor growth in mice [NIH]











5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE



Gasdermin E: A new approach to cancer immunotherapy that could have broad reach [Medical XPress]











5.12.2.1 IMMUNOTHÉRAPIES CAR-NK



Two-pronged attack on DNA repair could kill drug-resistant cancers [Institute of Cancer Research]











CAR Natural Killer Cell Therapy Safe and Effective in First Trial [JAMA]










5.12.4 IMMUNOTHÉRAPIES - ESSAIS



No Survival Benefit for Maintenance Avelumab in Advanced Gastric or Gastroesophageal Junction Cancer [ASCO Post]











5.12.5.1 IMMUNOTHÉRAPIES - BIOTECH



Cell Medica rebrands as Kuur, raises cash for CAR-NKT trials [Fierce Biotech]











J&J partner Legend plans IPO to fund CAR-T pipeline [Fierce Biotech]











5.12.6 IMMUNOTHÉRAPIES - AMM



Bristol Myers Squibb snags new liver cancer nod for Opdivo-Yervoy combo [Fierce Pharma]











U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) for Patients with Hepatocellular Carcinoma (HCC) Previously Treated with Sorafenib [BMS]











FDA approves Bristol Myers' liver cancer therapy [Reuters]











FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma [FDA]











5.2 PHARMA



Update on Phase III GY004 trial for cediranib added to Lynparza in platinum-sensitive relapsed ovarian cancer [AstraZeneca]











Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for JNJ-6372 for the Treatment of Non-Small Cell Lung Cancer [Janssen]











After hitting big in multiple myeloma, J&J, Genmab now have a new 'breakthrough' in NSCLC to boast about [EndPoints]











5.2.3 PHARMA - ÉCONOMIE



Analysts start to sort out which biopharma companies’ R&D plans are most threatened by a pandemic [EndPoints]











5.4 TRAITEMENTS - ECONOMIE



Non-Hodgkin lymphoma treatment gets an initial ‘no’ for NHS use in England [Cancer Research UK]











5.9 AACR



Facing coronavirus risk, a top cancer group postpones annual meeting [Biopharma Dive]











AACR Annual Meeting 2020: Notice Of Termination And Rescheduling [AACR]











6.6 PUBLICATIONS, POLITIQUES SCIENTIFIQUES



Hundreds of scientists have peer-reviewed for predatory journals [Nature]











6.7.1 IA/BIOINFORMATIQUE



The importance of transparency and reproducibility in artificial intelligence research [arXiv]











6.9 CONTROVERSES



Fired cancer scientist says ‘good people are being crushed’ by overzealous probes into possible Chinese ties [Science]